Develop innovative vaccine platforms targeting antiviral diseases and cancer. Advance multiple vaccine candidates, including those for SARS-CoV-2 and HPV. Now — the numbers.
angles, checked one by one.
The 2 that stand out are on screen; the rest are not shown.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
The stock sits at $0.09. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At last year’s rate of cash burn, the cash lasts less than a year. After that, the company needs to find new money.
The stock trades 97% below its five-year peak.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, earnings execution, the revenue breakdown.